Literature DB >> 1986554

Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites.

H Okumura1, T Aramaki, Y Katsuta, K Satomura, M Akaike, T Sekiyama, H Terada, M Ohsuga, H Komeichi, H Tsutsui.   

Abstract

The effect of plasma volume contraction induced by a 4-wk administration of spironolactone or furosemide on the hepatic venous pressure gradient was evaluated in consecutively allocated patients with cirrhosis and no ascites. In the spironolactone group (n = 15), the hepatic venous pressure gradient decreased significantly (p less than 0.005), by 21.8%, with a significant contraction of circulating plasma volume (p less than 0.01). Although there were no statistically significant correlations between the change in hepatic venous pressure gradient and changes in circulating plasma volume or in simultaneously determined systemic hemodynamics, a significant negative correlation (r = -0.74, p less than 0.01, n = 12) between the hepatic venous pressure gradient change and the post-treatment plasma aldosterone levels was found. However, in the furosemide group (n = 10), the hepatic venous pressure gradient and circulating plasma volume did not significantly decrease. Our data demonstrated a significant reduction in the hepatic venous pressure gradient on a chronic administration of spironolactone, which may have been due to volume contractions in patients with cirrhosis and no ascites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986554

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

Review 1.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

2.  Sodium homeostasis with chronic sodium loading in preascitic cirrhosis.

Authors:  F Wong; P Liu; L Blendis
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

3.  Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis.

Authors:  S Sugano; T Suzuki; M Nishio; H Makino; T Okajima
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

Review 4.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

5.  Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial.

Authors:  Binay-K De; Deep Dutta; Rimi Som; Pranab-K Biswas; Subrata-K Pal; Anirban Biswas
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

Review 6.  Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.

Authors:  Massimo Bolognesi; Marco Di Pascoli; Alberto Verardo; Angelo Gatta
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

7.  Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis.

Authors:  Elizabeth C Verna; Robert S Brown; Erica Farrand; Elsa M Pichardo; Catherine S Forster; David A Sola-Del Valle; Sarah H Adkins; Meghan E Sise; Juan A Oliver; Jai Radhakrishnan; Jonathan M Barasch; Thomas L Nickolas
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

8.  Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.

Authors:  Wei Luo; Ying Meng; Hong-Li Ji; Chun-Qiu Pan; Shan Huang; Chang-Hui Yu; Li-Ming Xiao; Kai Cui; Shu-Yuan Ni; Zhen-Shu Zhang; Xu Li
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.